NEW YORK, Jan. 10 -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.
Sutent more than doubled progression-free survival (P
